AbbVie Inc. (ABBV)
After hours:
| Previous close | 162.54 |
| Open | 164.15 |
| Bid | 164.25 x 800 |
| Ask | 164.68 x 800 |
| Day's range | 163.26 - 164.74 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,664,483 |
| Market cap | 290.829B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 59.95 |
| EPS (TTM) | 2.74 |
| Earnings date | 26 Apr 2024 |
| Forward dividend & yield | 6.20 (3.81%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 184.49 |
ZacksAbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
- Reuters
UPDATE 1-US FDA warns of harmful reactions to fake Botox injections
The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.
- Zacks
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
